RSNA 2022 Molecular Imaging

Road to RSNA 2022: Molecular Imaging Preview

By Will Morton, AuntMinnie.com staff writer
November 22, 2022

This year's nuclear medicine and molecular imaging program at RSNA 2022 resounds with the impact of theranostics on the lives of patients with prostate cancer, with prostate-specific membrane antigen (PSMA)-PET imaging taking center stage. Organizers even saw fit to title one scientific session "Prostate and Theranostics Potpourri."

Among the medley are several sessions that discuss how PET imaging with gallium-68 (Ga-68) PSMA-11 improves patient management for most prostate cancer patients and how the use of F-18 DCFPyL (Pylarify) can help when selecting men under consideration for focal ablative therapy.

Moreover, in another session, researchers will describe how nomograms based on Pylarify PET/CT can help guide the selection of the most suitable patients for imaging, potentially reducing unnecessary medical expenses.

F-18 FDG-PET/CT imaging makes another strong showing at this year's meeting, with one study offering evidence that the approach can have a significant impact on initial staging, restaging, clinical management, and outcomes for patients with soft-tissue and bone sarcomas. Another discusses the impact of F-18 FDG PET/MRI on therapeutic management of women with newly diagnosed breast cancer.

Exciting results from studies of other PET radiotracers will also be presented. For instance, somatostatin receptor (SSTR)-PET/CT appears to outperform standard histopathology for detecting liver metastases in differentiated neuroendocrine tumors (NET), according to one study we've highlighted. In another, researchers from the U.S. National Institutes of Health suggest that F-18 fluorodopa (FDOPA) should be the radiotracer of choice among four evaluated for diagnosing adrenal gland tumors.

Also, artificial intelligence (AI) research appears to be taking shape in molecular imaging, especially in Alzheimer's disease. One study we've highlighted discusses the development of an algorithm that appears able to distinguish between normal and mildly cognitively impaired individuals and patients with Alzheimer's disease across several different amyloid PET tracers.

Meanwhile, in the meeting's Learning Center, attendees can choose from 35 education exhibits beginning on Sunday, November 27. We've highlighted two of these below. In one, a nuclear medicine physician from Fargo, ND, where temperatures average 3° F in winter, will discuss triaging frostbite injuries with Tc-99m methylene diphosphonate (MDP) multiphase SPECT. In another, an expert from the Mayo Clinic in Rochester will offer advice on detecting the most common emergent diagnostic challenges radiologists face on PET, with a focus on newer radiotracers.

Keep reading for more highlights of some of the many molecular imaging research presentations and posters scheduled for this year's meeting. You can view the complete list of abstracts for the 2022 scientific and educational program on the RSNA 2022 website.

FDG-PET/MRI can guide breast cancer therapy changes
Sunday, November 27 | 9:00 a.m.-9:30 a.m. | S1-STCE-3 | Learning Center Theater
In this talk, researchers will discuss how F-18 FDG-PET/MRI leads to therapy changes in breast cancer patients with elevated pretest probability for distant metastases.
FDG-PET/CT improves management of patients with sarcomas
Sunday, November 27 | 10:30 a.m.-11:30 a.m. | S2-SSNMMI01-4 | Room E352
In this scientific session, a study will be presented on the impact of F-18 FDG-PET/CT imaging on initial staging, restaging, clinical management, and outcomes for patients with soft-tissue and bone sarcomas.
SSR-PET/CT outperforms biopsy for diagnosing liver NET metastases
Tuesday, November 29 | 9:30 a.m.-10:30 a.m. | T3-SSNMMI05-5 | Room E351
In this scientific session, a retrospective study will be presented that evaluated the accuracy of somatostatin receptor (SSR)-PET/CT for detecting liver metastases in differentiated neuroendocrine tumors (NETs).
F-18 FDOPA best for imaging adrenal tumors related to MEN 2
Tuesday, November 29 | 1:30 p.m.-2:00 p.m. | T6-STCE-4 | Learning Center Theater
In this molecular imaging scientific session, researchers will make the case that F-18 fluorodopa (FDOPA) should be the radiotracer of choice among four evaluated for diagnosing adrenal gland tumors related to multiple endocrine neoplasia type 2 (MEN 2).
Ga-68 PSMA-11 PET changes management for most patients
Wednesday, November 30 | 9:30 a.m.-10:30 a.m. | W3-SSNMMI06-2 | Room S502
Gallium-68 (Ga-68) prostate-specific membrane antigen (PSMA)-11 PET/CT and PET/MRI resulted in patient management changes in most clinical trial participants with prostate cancer, according to research presented in this session.
Pylarify improves management of patients considered for FT
Wednesday, November 30 | 9:30 a.m.-10:30 a.m. | W3-SSNMMI06-1 | Room S502
The role of F-18 DCFPyL (Pylarify) PET/MRI in the management of men considered for focal ablative therapies (FT) will be discussed in this session, with results suggesting the approach may exclude nearly 30% of patients from focal therapy.
Nomograms help predict positive Pylarify scans in prostate cancer patients
Wednesday, November 30 | 12:15 p.m.-12:45 p.m. | W5A-STCE-2 | Learning Center Theater
Nomograms may help guide the selection of the most suitable prostate cancer patients for F-18 DCFPyL-PET/CT (Pylarify) imaging, according to research presented in this session.
Which radiotracer is best for preoperative lymph node assessment?
Wednesday, November 30 | 3:00 p.m.-4:00 p.m. | W7-SSBR09-2 | Room E451B
In this scientific talk, researchers will compare the performance of F-18 FDG and F-18 fluoroethylcholine in preoperative lymph node assessment of breast cancer patients on PET/MRI.
Ga-68 DOTATATE PET/CT predicts outcomes in Lutathera patients
Thursday, December 1 | 9:30 a.m.-10:30 a.m. | R3-SSNMMI07-2 | Room S501
Patients with neuroendocrine tumors (NETs) who are at high risk for poor outcomes following peptide receptor radionuclide therapy (PRRT) can be identified with semi-automated quantitative analysis of gallium-68 (GA-68) DOTATATE PET/CT scans, according to research to be presented in this session.
AI model predicts early Alzheimer's disease
Thursday, December 1 | 9:30 a.m.-10:30 a.m. | R3-SSNR15-1 | Room N226
In this neuroradiology session, researchers will present details on an amyloid PET-based deep-learning algorithm for predicting Alzheimer's disease dementia that is generalizable across different amyloid PET radiotracers.
Recognizing PET emergent findings among various radiotracers
On Demand | NMMIEE-9 | Learning Center -- NMMI
In this exhibit, Mayo Clinic researchers in Rochester have prepared a presentation on methods to detect the most common emergent diagnostic challenges radiologists will face on PET, with a focus on newer radiotracers.
Winter is a SPECT time of year: Imaging frostbite
On Demand | NMMIEE-4 | Learning Center -- NMMI
In this course, nuclear medicine physician Dr. Erica Martin-Macintosh of Sanford Health in Fargo, ND, will discuss triaging frostbite injuries with multiphase technetium-99m methylenediphosphonate bone scintigraphy.